Index/Topics/Alzheimer's Trials 2026

Alzheimer's Trials 2026

Several high-profile Phase 3 Alzheimer's trials could report results in 2026, including Eli Lilly's anti-amyloid remternetug, Novo Nordisk's semaglutide EVOKE program, Annovis Bio's buntanetap pivotal study, the POLARIS-AD trial of AR1001, and a phase 3 metformin trial